| Original language | English |
|---|---|
| Pages (from-to) | 239-241 |
| Number of pages | 3 |
| Journal | Journal of Rheumatology |
| Volume | 49 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 31 Mar 2022 |
Bibliographical note
Funding Information:LCC is a National Institute for Health Research (NIHR) Clinician Scientist and Senior Clinical Research Fellow funded by an NIHR Clinician Scientist award. The research was supported by the NIHR Oxford Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health. 1L.C. Coates, MBChB, PhD, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford; 2W. Tillett, MBChB, BSc, PhD, Royal National Hospital for Rheumatic Diseases, and Department of Pharmacy and Pharmacology, University of Bath, Bath, UK. WT has received research funding, consulting or speaker fees from AbbVie, Amgen, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, and UCB. LCC has received grants/research support from AbbVie, Amgen, Celgene, Eli Lilly, Novartis and Pfizer; worked as a paid consultant for AbbVie, Amgen, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer, and UCB; and has been paid as a speaker for AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, Janssen, Medac, Novartis, Pfizer, and UCB. Address correspondence to Prof. L.C. Coates, Botnar Research Centre, Windmill Road, Oxford OX3 7LD, UK. Email: [email protected].
ASJC Scopus subject areas
- Immunology and Allergy
- Rheumatology
- Immunology